Nienke Wieringa

Nienke Wieringa

Auto-generated profile, based on publicly available information

Nienke Wieringa

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival. Significance: As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

17 June 2026
Verified
Other
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival.Significance:As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

4 March 2025
Verified
Other
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Clonal hematopoiesis gene panel

4 March 2025
Verified
Other
Open access
PDF file
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Additional details on CH mutations in HCT recipients and controls

4 March 2025
Verified
Other
Open access
PDF file
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Overview of screening and inclusion

17 June 2026
Verified
Other
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
Supplementary Table S1 from Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation